A Study of HR19024 in Subjects With Advanced Solid Tumor

• Status: Not yet recruiting
• Trial end date: 2023-07-30
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety，tolerability，pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

1. ECOG performance status 0 or 1

2. Histologically confirmed advanced solid tumor

3. Life expectancy of greater than or equal to (>=) 12 weeks

4. At least one measurable lesion is present according to the efficacy evaluation criteria for solid tumors (RECIST 1.1)

5. Able and willing to provide a written informed consent

Exclusion Criteria:

1. Subjects with unresolved toxicity （> CTCAE G1）of prior therapy at the time of enrolment

2. Subjects who had received anti-tumor treatments such as surgery, chemotherapy, radiotherapy recently